RxDoctor Payments Data

Dexter Hebert, OD

Optometrist · Thibodaux, LANPI 1346812179

Payments from drug & device makers

$3,804in general payments, 2019–2025

Across 147 payments — averaging $25.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$644
  • Oyster Point Pharma, Inc.$504
  • Tarsus Pharmaceuticals, Inc.$433
  • AbbVie$375
  • Harrow Eye, LLC$342
  • Johnson & Johnson Vision Care, Inc.$304
  • plus $1K from 7 others

What the payments were for

  • Food & beverage$3,804100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,804 in reported general payments places this provider in the 80th percentile of 500 optometrist providers in Louisiana.

See all optometrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$46,466
Medicare patients
284
Services billed
622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TyrvayaVarenicline Tartrate113$86,090
XiidraLifitegrast62$47,428
RestasisCyclosporine59$45,632
XdemvyLotilaner11$21,768
EysuvisLoteprednol Etabonate33$17,532
VevyeCyclosporine12$9,010
SimbrinzaBrinzolamide/Brimonidine Tart28$6,915
Cyclosporine21$4,845
CombiganBrimonidine Tartrate/Timolol11$4,144
Latanoprost220$1,820
Prednisolone Acetate37$1,649
Timolol Maleate88$800
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat33$349
Brimonidine Tartrate27$171
Doxycycline Hyclate17$114

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$504$86,090113 claims
AbbVieRestasis, Combigan$375$49,77670 claims
Bausch & Lomb Americas Inc.Xiidra$208$47,42862 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$433$21,76811 claims
Harrow Eye, LLCVevye$342$9,01012 claims
AlconSimbrinza$644$6,91528 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 500 optometrist providers in Louisiana.

Other optometrist in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →